IL273735B2 - A device for transdermal delivery of dextromethorphan - Google Patents
A device for transdermal delivery of dextromethorphanInfo
- Publication number
- IL273735B2 IL273735B2 IL273735A IL27373520A IL273735B2 IL 273735 B2 IL273735 B2 IL 273735B2 IL 273735 A IL273735 A IL 273735A IL 27373520 A IL27373520 A IL 27373520A IL 273735 B2 IL273735 B2 IL 273735B2
- Authority
- IL
- Israel
- Prior art keywords
- dextromethorphan
- day
- delivery device
- transdermal delivery
- adhesive
- Prior art date
Links
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 title claims description 335
- 229960001985 dextromethorphan Drugs 0.000 title claims description 328
- 230000037317 transdermal delivery Effects 0.000 title claims description 257
- 239000012790 adhesive layer Substances 0.000 claims description 134
- 239000010410 layer Substances 0.000 claims description 123
- 239000000853 adhesive Substances 0.000 claims description 114
- 230000001070 adhesive effect Effects 0.000 claims description 111
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 82
- 239000003961 penetration enhancing agent Substances 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 43
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 42
- 229960001404 quinidine Drugs 0.000 claims description 41
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 38
- 239000012848 Dextrorphan Substances 0.000 claims description 37
- 229950006878 dextrorphan Drugs 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 35
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 34
- -1 fatty acid esters Chemical class 0.000 claims description 28
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 27
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 24
- 229930195729 fatty acid Natural products 0.000 claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 24
- 206010054196 Affect lability Diseases 0.000 claims description 23
- 208000012902 Nervous system disease Diseases 0.000 claims description 22
- 229920001577 copolymer Polymers 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 20
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 16
- 208000025966 Neurological disease Diseases 0.000 claims description 14
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- 239000013464 silicone adhesive Substances 0.000 claims description 13
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 12
- 206010011224 Cough Diseases 0.000 claims description 12
- 239000005642 Oleic acid Substances 0.000 claims description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 12
- 229920002367 Polyisobutene Polymers 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 12
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 11
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 claims description 11
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 8
- 230000000954 anitussive effect Effects 0.000 claims description 7
- 239000000935 antidepressant agent Substances 0.000 claims description 7
- 229940005513 antidepressants Drugs 0.000 claims description 7
- 229940124584 antitussives Drugs 0.000 claims description 7
- 229920000058 polyacrylate Polymers 0.000 claims description 7
- 230000001430 anti-depressive effect Effects 0.000 claims description 6
- 229960001058 bupropion Drugs 0.000 claims description 6
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 4
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 4
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims description 4
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 4
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 4
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 4
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 4
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 4
- 229960003277 atazanavir Drugs 0.000 claims description 4
- 229960002626 clarithromycin Drugs 0.000 claims description 4
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 4
- 229960003914 desipramine Drugs 0.000 claims description 4
- 229960005156 digoxin Drugs 0.000 claims description 4
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 4
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 4
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 4
- 229960001936 indinavir Drugs 0.000 claims description 4
- 229960004130 itraconazole Drugs 0.000 claims description 4
- 229960004125 ketoconazole Drugs 0.000 claims description 4
- 229960002296 paroxetine Drugs 0.000 claims description 4
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 4
- 229960003634 pimozide Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000002356 single layer Substances 0.000 claims description 4
- 229960002784 thioridazine Drugs 0.000 claims description 4
- AKOAEVOSDHIVFX-UHFFFAOYSA-N Hydroxybupropion Chemical compound OCC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 AKOAEVOSDHIVFX-UHFFFAOYSA-N 0.000 claims description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 138
- 210000003491 skin Anatomy 0.000 description 134
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 65
- 230000004907 flux Effects 0.000 description 48
- 208000035475 disorder Diseases 0.000 description 35
- 238000009472 formulation Methods 0.000 description 31
- 201000010099 disease Diseases 0.000 description 30
- 238000000338 in vitro Methods 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 21
- 239000003623 enhancer Substances 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 230000036470 plasma concentration Effects 0.000 description 16
- 206010010904 Convulsion Diseases 0.000 description 15
- MRUNQKQTAMUPRF-PUTLROBFSA-N nuedexta Chemical compound Br.OS(O)(=O)=O.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21.C1C([C@H](C2)C=C)CCN2[C@H]1[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C1C([C@H](C2)C=C)CCN2[C@H]1[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 MRUNQKQTAMUPRF-PUTLROBFSA-N 0.000 description 15
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 15
- 230000001186 cumulative effect Effects 0.000 description 14
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 13
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 208000018737 Parkinson disease Diseases 0.000 description 11
- 238000013461 design Methods 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 10
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 206010008025 Cerebellar ataxia Diseases 0.000 description 9
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 9
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 229910052805 deuterium Inorganic materials 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 229940037869 nuedexta Drugs 0.000 description 9
- 208000002320 spinal muscular atrophy Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 206010026749 Mania Diseases 0.000 description 8
- 208000024714 major depressive disease Diseases 0.000 description 8
- 208000011117 substance-related disease Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000019022 Mood disease Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 102000014461 Ataxins Human genes 0.000 description 6
- 108010078286 Ataxins Proteins 0.000 description 6
- 206010003805 Autism Diseases 0.000 description 6
- 208000020706 Autistic disease Diseases 0.000 description 6
- 208000020925 Bipolar disease Diseases 0.000 description 6
- 208000010482 CADASIL Diseases 0.000 description 6
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 6
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 6
- 206010029350 Neurotoxicity Diseases 0.000 description 6
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 6
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 206010044221 Toxic encephalopathy Diseases 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 6
- 238000005266 casting Methods 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 6
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 208000005264 motor neuron disease Diseases 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 231100000228 neurotoxicity Toxicity 0.000 description 6
- 230000007135 neurotoxicity Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 5
- 229920003083 Kollidon® VA64 Polymers 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 206010057852 Nicotine dependence Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 208000025569 Tobacco Use disease Diseases 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 229940070721 polyacrylate Drugs 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 206010003591 Ataxia Diseases 0.000 description 4
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- 208000016285 Movement disease Diseases 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
- 208000004550 Postoperative Pain Diseases 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 4
- 208000018839 Wilson disease Diseases 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 208000028683 bipolar I disease Diseases 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- CYKDLUMZOVATFT-UHFFFAOYSA-N ethenyl acetate;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=O)OC=C CYKDLUMZOVATFT-UHFFFAOYSA-N 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 201000003631 narcolepsy Diseases 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 201000009032 substance abuse Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 3
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 3
- 206010006550 Bulimia nervosa Diseases 0.000 description 3
- 206010008027 Cerebellar atrophy Diseases 0.000 description 3
- 206010008748 Chorea Diseases 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 3
- 208000012661 Dyskinesia Diseases 0.000 description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
- 208000009829 Lewy Body Disease Diseases 0.000 description 3
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 3
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 3
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 3
- 208000012583 Menkes disease Diseases 0.000 description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
- 208000009905 Neurofibromatoses Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010033885 Paraparesis Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 201000009916 Postpartum depression Diseases 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 3
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000002548 Spastic Paraparesis Diseases 0.000 description 3
- 208000021017 Weight Gain Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 3
- 229960000528 amlodipine Drugs 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 208000025748 atypical depressive disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 229960002504 capsaicin Drugs 0.000 description 3
- 235000017663 capsaicin Nutrition 0.000 description 3
- 208000025434 cerebellar degeneration Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000026725 cyclothymic disease Diseases 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 3
- 208000024732 dysthymic disease Diseases 0.000 description 3
- 239000004811 fluoropolymer Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229960002870 gabapentin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 201000004931 neurofibromatosis Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 239000003402 opiate agonist Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
- 208000026961 psychosexual disease Diseases 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001148 spastic effect Effects 0.000 description 3
- 208000003755 striatonigral degeneration Diseases 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 229960004380 tramadol Drugs 0.000 description 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 206010058504 Ballismus Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 208000005793 Restless legs syndrome Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 206010040703 Simple partial seizures Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000027522 Sydenham chorea Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 240000004308 marijuana Species 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920006264 polyurethane film Polymers 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960004482 quinidine sulfate Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 208000012672 seasonal affective disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000002849 spasmodic dystonia Diseases 0.000 description 2
- 208000027765 speech disease Diseases 0.000 description 2
- 208000005809 status epilepticus Diseases 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- QTYYIZYAWHBAHQ-UHFFFAOYSA-N 3-(3-amino-2,4,6-trinitrophenyl)-2,4,6-trinitroaniline Chemical compound NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C=2C(=C(N)C(=CC=2[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)=C1[N+]([O-])=O QTYYIZYAWHBAHQ-UHFFFAOYSA-N 0.000 description 1
- IUWVYVOQTFVXKL-UHFFFAOYSA-N 4-decyl-1,3-oxazolidin-2-one Chemical compound CCCCCCCCCCC1COC(=O)N1 IUWVYVOQTFVXKL-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000009017 Athetosis Diseases 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 208000001573 Cataplexy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008138 Cerebral venous thrombosis Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 229920005987 OPPANOL® Polymers 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229910020175 SiOH Inorganic materials 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical group CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000008965 epilepsia partialis continua Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000004717 laryngeal muscle Anatomy 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical class CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 208000011293 voice disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568028P | 2017-10-04 | 2017-10-04 | |
| US201862680182P | 2018-06-04 | 2018-06-04 | |
| PCT/US2018/054178 WO2019070864A1 (en) | 2017-10-04 | 2018-10-03 | DEVICE FOR TRANSDERMAL DEXTROMETHORPHAN DELIVERY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273735A IL273735A (en) | 2020-05-31 |
| IL273735B1 IL273735B1 (en) | 2024-04-01 |
| IL273735B2 true IL273735B2 (en) | 2024-08-01 |
Family
ID=65994772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273735A IL273735B2 (en) | 2017-10-04 | 2018-10-03 | A device for transdermal delivery of dextromethorphan |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11382869B2 (https=) |
| EP (1) | EP3691641A4 (https=) |
| JP (2) | JP2020536953A (https=) |
| KR (1) | KR20200062254A (https=) |
| CN (1) | CN111343980B (https=) |
| AU (1) | AU2018345723B2 (https=) |
| BR (1) | BR112020006723A2 (https=) |
| CA (1) | CA3078369A1 (https=) |
| IL (1) | IL273735B2 (https=) |
| MX (1) | MX2020003044A (https=) |
| TW (1) | TWI795446B (https=) |
| WO (1) | WO2019070864A1 (https=) |
| ZA (1) | ZA202001834B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
| EP4125902A4 (en) * | 2020-03-30 | 2024-05-22 | Shinkei Therapeutics, Inc. | TRANSDERMAL ADMINISTRATION OF DEXTROMETHORPHAN |
| EP4183391A4 (en) * | 2020-07-20 | 2024-04-17 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION AND ITS USE |
| AU2022207514A1 (en) * | 2021-01-18 | 2023-07-27 | Antecip Bioventures Ii Llc | Combination of an antidepressant and dextromethorphan for neuropsychiatric conditions |
| CN113720944B (zh) * | 2021-09-30 | 2023-04-28 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊含量的检测方法 |
| TW202430177A (zh) * | 2022-10-06 | 2024-08-01 | 美商神經治療股份有限公司 | 右旋美索芬之經皮輸送 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335030B1 (en) * | 1996-04-23 | 2002-01-01 | Pharmacia & Upjohn Ab | Transdermally administered dextromethorphan as antitussive agent |
| US20070248657A1 (en) * | 2006-04-25 | 2007-10-25 | Smith David J | Multi-compartment transdermal pain control device |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3020630B2 (ja) * | 1991-03-27 | 2000-03-15 | 三井化学株式会社 | 薬物投与用粘着剤 |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| JP3021661B2 (ja) * | 1994-03-07 | 2000-03-15 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| SI1530469T1 (sl) * | 2002-08-20 | 2009-06-30 | Euro Celtique Sa | Transdermalna odmerna oblika, ki obsega aktivno sredstvo in antagonist v obliki soli in v obliki proste baze |
| KR20060126701A (ko) * | 2003-12-10 | 2006-12-08 | 애크럭스 디디에스 피티와이 리미티드 | 경피 또는 국소 약물 전달에 따른 원치않는 효과의치료방법 |
| US20060223786A1 (en) | 2005-04-01 | 2006-10-05 | Smith David J | Transdermal pain control method and device |
| ATE481096T1 (de) * | 2005-04-06 | 2010-10-15 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
| EP1986639A4 (en) * | 2006-02-03 | 2010-04-28 | Avanir Pharmaceuticals | PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES |
| CA2676133A1 (en) * | 2006-10-09 | 2008-04-17 | Smithkline Beecham Corporation | Compositions for reducing nicotine withdrawal symptoms and/or tobacco usage |
| WO2009021058A2 (en) | 2007-08-06 | 2009-02-12 | Trinity Labortories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| WO2010062690A1 (en) | 2008-10-30 | 2010-06-03 | Concert Pharmaceuticals Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| RU2544702C2 (ru) * | 2009-04-24 | 2015-03-20 | Хенкель Корпорейшн | Клеи на основе силикон-акрилового гибридного полимера |
| US20140051718A1 (en) * | 2012-04-16 | 2014-02-20 | Antecip Bioventures Ii Llc | Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan |
| MY179696A (en) | 2013-11-05 | 2020-11-11 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
-
2018
- 2018-10-02 TW TW107134828A patent/TWI795446B/zh active
- 2018-10-03 US US16/753,471 patent/US11382869B2/en active Active
- 2018-10-03 JP JP2020540680A patent/JP2020536953A/ja active Pending
- 2018-10-03 EP EP18864063.5A patent/EP3691641A4/en active Pending
- 2018-10-03 CA CA3078369A patent/CA3078369A1/en active Pending
- 2018-10-03 KR KR1020207011696A patent/KR20200062254A/ko not_active Ceased
- 2018-10-03 WO PCT/US2018/054178 patent/WO2019070864A1/en not_active Ceased
- 2018-10-03 AU AU2018345723A patent/AU2018345723B2/en active Active
- 2018-10-03 BR BR112020006723-7A patent/BR112020006723A2/pt unknown
- 2018-10-03 IL IL273735A patent/IL273735B2/en unknown
- 2018-10-03 MX MX2020003044A patent/MX2020003044A/es unknown
- 2018-10-03 CN CN201880072989.3A patent/CN111343980B/zh active Active
-
2020
- 2020-03-23 ZA ZA2020/01834A patent/ZA202001834B/en unknown
-
2022
- 2022-07-06 US US17/858,471 patent/US20220331264A1/en not_active Abandoned
-
2023
- 2023-08-25 JP JP2023136898A patent/JP7609943B2/ja active Active
- 2023-10-19 US US18/381,849 patent/US20240189252A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335030B1 (en) * | 1996-04-23 | 2002-01-01 | Pharmacia & Upjohn Ab | Transdermally administered dextromethorphan as antitussive agent |
| US20070248657A1 (en) * | 2006-04-25 | 2007-10-25 | Smith David J | Multi-compartment transdermal pain control device |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3078369A1 (en) | 2019-04-11 |
| US20240189252A1 (en) | 2024-06-13 |
| EP3691641A4 (en) | 2021-04-07 |
| MX2020003044A (es) | 2020-08-13 |
| ZA202001834B (en) | 2024-10-30 |
| IL273735B1 (en) | 2024-04-01 |
| CN111343980A (zh) | 2020-06-26 |
| AU2018345723A8 (en) | 2020-04-23 |
| JP7609943B2 (ja) | 2025-01-07 |
| BR112020006723A2 (pt) | 2020-10-06 |
| WO2019070864A1 (en) | 2019-04-11 |
| EP3691641A1 (en) | 2020-08-12 |
| US20220331264A1 (en) | 2022-10-20 |
| AU2018345723A1 (en) | 2020-04-16 |
| RU2020115169A3 (https=) | 2022-02-16 |
| US11382869B2 (en) | 2022-07-12 |
| US20200323788A1 (en) | 2020-10-15 |
| IL273735A (en) | 2020-05-31 |
| TW201922232A (zh) | 2019-06-16 |
| RU2020115169A (ru) | 2021-11-08 |
| JP2020536953A (ja) | 2020-12-17 |
| CN111343980B (zh) | 2024-02-27 |
| AU2018345723B2 (en) | 2024-09-19 |
| JP2023159366A (ja) | 2023-10-31 |
| KR20200062254A (ko) | 2020-06-03 |
| TWI795446B (zh) | 2023-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240216358A1 (en) | Transdermal delivery of dextromethorphan | |
| US20240189252A1 (en) | Dextromethorphan transdermal delivery device | |
| EP3338768B1 (en) | Transdermal therapeutic system containing asenapine | |
| JP5795264B2 (ja) | 抗認知症薬物の経皮吸収製剤 | |
| US11559497B2 (en) | Transdermal drug delivery system for ketamine | |
| RU2795729C2 (ru) | Устройство для трансдермальной доставки декстрометорфана | |
| EP4598514A1 (en) | Transdermal delivery of dextromethorphan | |
| HK40028806A (en) | Dextromethorphan transdermal delivery device | |
| HK40028806B (zh) | 右美沙芬经皮递送装置 | |
| HK40129313A (zh) | 右美沙芬的经皮递送 | |
| JP2022532635A (ja) | 高含量のドネペジル又はその塩を含む経皮吸収製剤 |